312
Views
20
CrossRef citations to date
0
Altmetric
Articles

EXPERIENCE WITH CEFEPIME VERSUS MEROPENEM AS EMPIRIC MONOTHERAPY FOR NEUTROPENIA AND FEVER IN PEDIATRIC PATIENTS WITH SOLID TUMORS

, MD, , MD, , MD, , MD & , MD
Pages 245-253 | Received 09 Sep 2005, Accepted 02 Dec 2005, Published online: 09 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Metin Demirkaya, Solmaz Çelebi, Betül Sevinir & Mustafa Hacımustafaoglu. (2013) Randomized Comparison of Piperacillin–Tazobactam Plus Amikacin Versus Cefoperazone-Sulbactam Plus Amikacin for Management of Febrile Neutropenia in Children with Lymphoma and Solid Tumors. Pediatric Hematology and Oncology 30:2, pages 141-148.
Read now
Hacı Ahmet Demir, Tezer Kutluk, Mehmet Ceyhan, Begül Yağcı-Küpeli, Canan Akyüz, Bülent Cengiz, Ali Varan, Ateş Kara, Bilgehan Yalçın, Gülten Seçmeer & Münevver Büyükpamukçu. (2011) Comparison of Sulbactam-Cefoperazone with Carbapenems as Empirical Monotherapy for Febrile Neutropenic Children with Lymphoma and Solid Tumors. Pediatric Hematology and Oncology 28:4, pages 299-310.
Read now

Articles from other publishers (18)

Xinmei Tan, Yan Li, Jiaxi Xi, Sitong Guo, Henghai Su, Xiaoyu Chen & Xueyan Liang. (2021) Comparative efficacy and safety of antipseudomonal β-lactams for pediatric febrile neutropenia. Medicine 100:50, pages e27266.
Crossref
Ying Wang, Zhichao Du, Yongdong Chen, Yugang Liu & Zhitang Yang. (2021) Meta-analysis: combination of meropenem vs ceftazidime and amikacin for empirical treatment of cancer patients with febrile neutropenia. Medicine 100:8, pages e24883.
Crossref
Tatsuo Oyake, Yuka Takemasa-Fujisawa, Norifumi Sugawara, Takahiro Mine, Yasuhiko Tsukushi, Ichiro Hanamura, Yukiteru Fujishima, Yusei Aoki, Shugo Kowata, Shigeki Ito & Yoji Ishida. (2019) Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study. Annals of Hematology 98:5, pages 1209-1216.
Crossref
Saber Jan, Braveen Ragunanthan, Sandra R. DiBrito, Omolabake Alabi & Maria Gutierrez. (2018) Cefepime Efficacy and Safety in Children: A Systematic Review and Meta-analysis. Frontiers in Pediatrics 6.
Crossref
Nikolaos Andreatos, Myrto Eleni Flokas, Anna Apostolopoulou, Michail Alevizakos & Eleftherios Mylonakis. (2017) The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases 4:3.
Crossref
Paula D. RobinsonThomas LehrnbecherRobert PhillipsL. Lee DupuisLillian Sung. (2016) Strategies for Empiric Management of Pediatric Fever and Neutropenia in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review of Randomized Trials. Journal of Clinical Oncology 34:17, pages 2054-2060.
Crossref
Masaki Fujita, Takemasa Matsumoto, Yuuichi Inoue, Hiroshi Wataya, Koichi Takayama, Masayuki Ishida, Noriyuki Ebi, Junji Kishimoto & Yukito Ichinose. (2016) The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study. Journal of Infection and Chemotherapy 22:4, pages 235-239.
Crossref
Arif Manji, Thomas Lehrnbecher, L. Lee Dupuis, Joseph Beyene & Lillian Sung. (2011) A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Supportive Care in Cancer 20:10, pages 2295-2304.
Crossref
Arif Manji, Thomas Lehrnbecher, L. Lee Dupuis, Joseph Beyene & Lillian Sung. (2012) A Meta-analysis of Antipseudomonal Penicillins and Cephalosporins in Pediatric Patients With Fever and Neutropenia. Pediatric Infectious Disease Journal 31:4, pages 353-359.
Crossref
Mical Paul, Dafna Yahav, Assaf Bivas, Abigail Fraser & Leonard Leibovici. (2011) Cochrane Review: Anti‐pseudomonal beta‐lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta‐lactams. Evidence-Based Child Health: A Cochrane Review Journal 6:6, pages 2026-2185.
Crossref
Alison G. Freifeld, Eric J. Bow, Kent A. Sepkowitz, Michael J. Boeckh, James I. Ito, Craig A. Mullen, Issam I. Raad, Kenneth V. Rolston, Jo-Anne H. Young & John R. Wingard. (2011) Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 52:4, pages e56-e93.
Crossref
Alison G. Freifeld, Eric J. Bow, Kent A. Sepkowitz, Michael J. Boeckh, James I. Ito, Craig A. Mullen, Issam I. Raad, Kenneth V. Rolston, Jo-Anne H. Young & John R. Wingard. (2011) Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 52:4, pages 427-431.
Crossref
Mical Paul, Dafna Yahav, Assaf Bivas, Abigail Fraser & Leonard Leibovici. (2010) Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database of Systematic Reviews 2015:2.
Crossref
Elisabeth E. Adderson, Patricia M. Flynn & James M. Hoffman. (2010) Efficacy and Safety of Cefepime in Pediatric Patients: A Systematic Review and Meta-Analysis. The Journal of Pediatrics 157:3, pages 490-495.e1.
Crossref
X. Durrmeyer & R. Cohen. (2010) Utilisation des carbapénèmes en pédiatrie. Archives de Pédiatrie 17, pages S163-S170.
Crossref
Sema Vural, Ela Erdem, Seda Geylani Gulec, Yildiz Yildirmak & Rejin Kebudi. (2010) Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatrics International 52:2, pages 262-267.
Crossref
Ryoji Kobayashi, Tomonobu Sato, Masahide Nakajima, Makoto Kaneda & Akihiro Iguchi. (2009) Piperacillin/Tazobactam Plus Ceftazidime Versus Sulbactam/Ampicillin Plus Aztreonam as Empirical Therapy for Fever in Severely Neutropenic Pediatric Patients. Journal of Pediatric Hematology/Oncology 31:4, pages 270-273.
Crossref
David J. Weber. (2006) Collateral damage and what the future might hold. The need to balance prudent antibiotic utilization and stewardship with effective patient management. International Journal of Infectious Diseases 10, pages S17-S24.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.